title: Pharmaceutical quality of nine generic orlistat products compared with Xenical(r).
abstract: OBJECTIVE
  To compare the pharmaceutical quality of Xenical (chemically produced orlistat) with nine generic products, each produced by fermentation processes.
  
  
  METHODS
  Xenical 120 mg capsules (Roche, Basel, Switzerland) were used as reference material. Generic products were from India, Malaysia, Argentina, Philippines, Uruguay, and Taiwan. Colour, melting temperature, crystalline form, particle size, capsule fill mass, active pharmaceutical ingredient content, amount of impurities, and dissolution were compared. Standard physical and chemical laboratory tests were those developed by Roche for Xenical.
  
  
  RESULTS
  All nine generic products failed the Xenical specifications in four or more tests, and two generic products failed in seven tests. A failure common to all generic products was the amount of impurities present, mostly due to different by-products, including side-chain homologues not present in Xenical. Some impurities were unidentified. Two generic products tested failed the dissolution test, one product formed a capsule-shaped agglomerate on storage and resulted in poor (</=15%) dissolution. Six generic products were powder formulations.
  
  
  CONCLUSIONS
  All tested generic orlistat products were pharmaceutically inferior to Xenical. The high levels of impurities in generic orlistat products are a major safety and tolerability concern.
authors.affiliation: Department of Pharmaceutics, London School of Pharmacy, London, UK. peter.taylor@pharmacy.ac.uk
authors.forename: Peter W
authors.initials: PW
authors.lastname: Taylor
authors.forename: Isabelle
authors.initials: I
authors.lastname: Arnet
authors.forename: Anton
authors.initials: A
authors.lastname: Fischer
authors.forename: Iain N
authors.initials: IN
authors.lastname: Simpson
mesh_terms: D019440:Anti-Obesity Agents / Q000737:chemistry / Q000592:standards*; D002214:Capsules; D003460:Crystallization; D004304:Dosage Forms; D016568:Drugs, Generic / Q000737:chemistry / Q000592:standards*; D006801:Humans; D007783:Lactones / Q000737:chemistry / Q000592:standards*; D000077403:Orlistat; D010316:Particle Size; D011786:Quality Control; D012015:Reference Standards; D012996:Solutions; D013810:Therapeutic Equivalency; D044366:Transition Temperature
chemical_list: D019440:Anti-Obesity Agents; D002214:Capsules; D004304:Dosage Forms; D016568:Drugs, Generic; D007783:Lactones; D012996:Solutions; D000077403:Orlistat
references.citation: Curr Med Res Opin. 2006 Mar;22(3):603-15
references.pmid: 16574043
references.citation: Clin Drug Investig. 2005;25(2):135-52
references.pmid: 17523763
references.citation: Ann Pharmacother. 2001 Mar;35(3):314-28
references.pmid: 11261530
references.citation: Adv Ther. 2000 May-Jun;17(3):167-78
references.pmid: 11183454
references.citation: Curr Med Res Opin. 2006 Apr;22(4):709-20
references.pmid: 16684432
references.citation: Am J Physiol Gastrointest Liver Physiol. 2001 Jul;281(1):G16-28
references.pmid: 11408251
references.citation: J Chemother. 2003 Aug;15(4):357-68
references.pmid: 12962364
references.citation: Clin Pharmacol Ther. 1994 Jul;56(1):82-5
references.pmid: 8033498
references.citation: Biochem J. 1988 Dec 1;256(2):357-61
references.pmid: 3223916
references.citation: Biochim Biophys Acta. 1988 Oct 14;962(3):308-16
references.pmid: 3167082